Cantargia AB

The positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp

Sweden’s Cantargia AB is moving into the spotlight after raising more funds to advance its lead asset nadunolimab through late-stage trials in non-small cell lung and pancreatic cancers. The Stockho

Things appear to be picking up at Glenmark Pharmaceuticals Limited ’s innovation spin-out, Ichnos Sciences, Inc. , with the US-headquartered firm striking its first licensing deal with Almirall S.A

Many classical disease targets have a number of therapeutic drug options, like the statins and the H2-receptor antagonists. Historically, pharmaceutical discovery groups have followed each other aroun